2023 Archives - EpicentRx

EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023

Nov 6, 2023

TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ -- EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the...

United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting “nibrozetone” as New Generic Name for EpicentRx’s Lead Small Molecule NLRP3 Inhibitor, RRx-001

Jul 6, 2023

New USAN name, a shortening of its chemical name, signifies a novel therapeutic class Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs TORREY...

EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 7, 2023

Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ --...

EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis

Mar 29, 2023

FDA also accepts company's Investigational New Drug (IND) application to initiate a follow-on phase 2b clinical trial, called KEVLARx TORREY PINES, CA, March 29, 2023 — EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration (FDA)...

EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer’s and Parkinson’s diseases in Multiple Disease Models

Mar 28, 2023

TORREY PINES, Calif., March 28, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer’s & Parkinson’s Diseases taking...

Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs

Mar 21, 2023

RRx-001 is a small molecule direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegeneration, and other inflammatory conditions RRx-001 is the most advanced direct NLRP3 inflammasome inhibitor in clinical development, having been evaluated in over 300...

Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors

Mar 15, 2023

The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging but preliminary anticancer signal in cold, non-immunogenic tumors TORREY PINES, Calif., March 15, 2023 /PRNewswire/ -- EpicentRx, a leading...

EpicentRx Presents Poster on the Nephroprotective Effects of RRx-001 in Patients with Solid Tumors that Receive Cisplatin/Etoposide at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Feb 15, 2023

TORREY PINES, Calif., February 15, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced that it has been selected for a poster...

EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Jan 20, 2023

Torrey Pines, Calif., January 20, 2023 - EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of...

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

Jan 19, 2023

Results from PREVLAR trial Demonstrate RRx-001 protects against severe oral mucositis or blistering from radiation in first line head and neck cancer Study published in International Journal of Radiation Oncology, Biology and Physics, also known as The Red Journal...